CD4 and neoplasm: The tumor-associated T helper (TH) cells (CD3+ CD4+ FoxP3−) are central in augmenting an optimal adaptive anticancer response and a significant increase in PCL8-U75 L-OHP liposome–treated tumors compared to all other treatments (Fig. 4D).